全、新、優(yōu)、品、好四大特點(diǎn)：

抑制基因抗體（野生型P53）說明書 全：公司提供上萬種產(chǎn)品，涵蓋了生物試劑，elisa試劑盒，標(biāo)準(zhǔn)品，培養(yǎng)基，原裝耗材，抗體、培養(yǎng)基、ATCC細(xì)胞等，基本上各種科研所需產(chǎn)品在我司都能找到。

新：產(chǎn)品更新速度較快，基本上每周都有新產(chǎn)品出現(xiàn)。

優(yōu)：產(chǎn)品質(zhì)量好，投訴比較少。

好：我公司具有優(yōu)質(zhì)的技術(shù)團(tuán)隊(duì)，產(chǎn)品一旦售出，實(shí)驗(yàn)過程中遇到困難可提供在線技術(shù)咨詢。使您使用產(chǎn)品時(shí)沒有任何的后顧之憂。

抑制基因抗體（野生型P53）說明書 英文名稱  Anti-P53(wt-p53)

中文名稱  抑制基因抗體（野生型P53）說明書 

別    名 Widespread p53; Wtp53; Antigen NY-CO-13; Cellular tumor antigen p53; Cys 51 Stop; HGNC11998; LFS1; p53; p53 Cellular Tumor Antigen; p53 Tumor Suppressor; Phosphoprotein p53; TP53; Transformation related protein 53; TRP53; Tumor protein p53; Tumour Protein p53; P53_HUMAN; TP53.

產(chǎn)品屬性：

濃    度  1mg/1ml

規(guī) 格  0.1ml/100μg 0.2ml/200μg

抗體來源  Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Dog, Pig, Horse, Rabbit, Sheep

產(chǎn)品類型   一抗  

研究領(lǐng)域     信號(hào)轉(zhuǎn)導(dǎo) 細(xì)胞凋亡

蛋白分子量  predicted molecular weight: 53kDa 

性    狀   Lyophilized or Liquid

免 疫 原  KLH conjugated synthetic peptide derived from human P53 C-terminus

亞    型  IgG

純化方法   affinity purified by Protein A

儲(chǔ) 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

抑制基因抗體（野生型P53）說明書 產(chǎn)品應(yīng)用   WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons (PMIDs: 12032546, 20937277). [provided by RefSeq, Feb 2013].

Function : Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis.

Subunit : Interacts with AXIN1. Probably part of a complex consisting of TP53, HIPK2 and AXIN1 (By similarity). Binds DNA as a homotetramer. Interacts with histone acetyltransferases EP300 and methyltransferases HRMT1L2 and CARM1, and recruits them to promoters. In vitro, the interaction of TP53 with cancer-associated/HPV (E6) viral proteins leads to ubiquitination and degradation of TP53 giving a possible model for cell growth regulation. This complex formation requires an additional factor, E6-AP, which stably associates with TP53 in the presence of E6. Interacts (via C-terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts with ING4; this interaction may be indirect. Found in a complex with CABLES1 and TP73. Interacts with HIPK1, HIPK2, and TP53INP1. Interacts with WWOX. May interact with HCV core protein. Interacts with USP7 and SYVN1. Interacts with HSP90AB1. Interacts with CHD8; leading to recruit histone H1 and prevent transactivation activity (By similarity). Interacts with ARMC10, BANP, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1. Interacts with YWHAZ; the interaction enhances TP53 transcriptional activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this interaction. Interacts (via DNA-binding domain) with MAML1 (via N-terminus). Interacts with MKRN1. Interacts with PML (via C-terminus). Interacts with MDM2; leading to ubiquitination and proteasomal degradation of TP53. Directly interacts with FBXO42; leading to ubiquitination and degradation of TP53. Interacts (phosphorylated at Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates stress-induced TP53-dependent inhibition of cell proliferation. Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-382) with L3MBTL1. Isoform 1 interacts with isoform 2 and with isoform 4. Interacts with GRK5. Binds to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage. Interacts with CDK5 in neurons. Interacts with AURKB, UHRF2 and NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes ubiquitination by MDM2. Interacts with PRKCG. Interacts with human cytomegalovirus/HHV-5 protein UL123.

Subcellular Location : Cytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Note=Interaction with BANP promotes nuclear localization. Recruited into PML bodies together with CHEK2.

Isoform 2: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.

Isoform 3: Nucleus. Cytoplasm. Note=Localized in the nucleus in most cells but found in the cytoplasm in some cells.

Isoform 4: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm following cell stress.

Isoform 7: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.

Isoform 8: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli.

Isoform 9: Cytoplasm.

Tissue Specificity : Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine.

Post-translational modifications : Acetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence.

Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1. Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which prevents ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen species (ROS), promoting p53/TP53-mediated apoptosis. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to DNA damage. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with BANP. Phosphorylated by NUAK1 at Ser-15 and Ser-392; was initially thought to be mediated by STK11/LKB1 but it was later shown that it is indirect and that STK11/LKB1-dependent phosphorylation is probably mediated by downstream NUAK1 (PubMed:21317932). It is unclear whether AMP directly mediates phosphorylation at Ser-15. Phosphorylated on Thr-18 by isoform 1 and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of VRK2 results in a reduction in ubiquitination by MDM2 and an increase in acetylation by EP300. Stabilized by CDK5-mediated phosphorylation in response to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser-46, leading to accumulation of p53/TP53, particularly in the nucleus, thus inducing the transactivation of p53/TP53 target genes. Phosphorylated at Ser-315 and Ser-392 by CDK2 in response to DNA-damage.

Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A.

May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line.

Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation. Ubiquitinated by RFWD3, which works in cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome. Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation. Deubiquitinated by USP10, leading to its stabilization. Ubiquitinated by TRIM24, which leads to proteasomal degradation. Ubiquitination by TOPORS induces degradation. Deubiquitination by USP7, leading to stabilization. Isoform 4 is monoubiquitinated in an MDM2-independent manner.

Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation. Monomethylated at Lys-370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity. Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and EHMT2. Monomethylated at Lys-382 by SETD8, promoting interaction with L3MBTL1 and leading to repress transcriptional activity. Demethylation of dimethylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation.

Sumoylated by SUMO1.

DISEASE : Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.

Defects in TP53 are a cause of esophageal cancer (ESCR) [MIM:133239].

Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.

Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC)

Defects in TP53 are a cause of lung cancer (LNCR) [MIM:211980]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.

Defects in TP53 are a cause of choroid plexus papilloma (CPLPA) [MIM:260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood.

Defects in TP53 are a cause of adrenocortical carcinoma (ADCC) [MIM:202300]. ADCC is a rare childhood tumor of the adrenal cortex. It occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome and is a component tumor in Li-Fraumeni yndrome.

Similarity : Belongs to the p53 family.

Database links : NCBI Reference Sequence: NP_001119584.1

UniProtKB/Swiss-Prot: P04637.4

wtp53廣泛的研究發(fā)現(xiàn)P53抑制基因?qū)?0%以上的人類具有抑制突變的功能。P53蛋白水平在正常細(xì)胞中表達(dá)低，在DNA突變時(shí)或各種各樣細(xì)胞遇難信號(hào)時(shí)反應(yīng)增加。該基因突變或缺失是導(dǎo)致許多發(fā)生的原因。

野生型P53(wt-p53)可誘導(dǎo)細(xì)胞凋亡，并通過細(xì)胞凋亡抑制，而P53的突變或缺失則可抑制野生型P53的功能，使得缺陷細(xì)胞得以存活下來，從而導(dǎo)致發(fā)生。

P53同時(shí)也是細(xì)胞凋亡的調(diào)控因子。此抗體可用于P53的研究。

實(shí)驗(yàn)流程：

正在熱銷的相關(guān)產(chǎn)品：

Anti-Phospho-Estrogen Receptor α (Ser118) /FITC 熒光素標(biāo)記兔抗人、大、小鼠磷酸化雌激素受體α抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-MTF-1/FITC 熒光素標(biāo)記金屬反應(yīng)轉(zhuǎn)錄因子-1抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh C19orf47 19號(hào)染色體開放閱讀框47抗體 規(guī)格 0.2ml

Alpha-Synuclein 核突觸蛋白(抗原) 0.5mg

HSPB2 英文名稱： 熱休克蛋白B2抗體 0.1ml

Rhesus antibody Rh RPL15 核糖體蛋白L15抗體 規(guī)格 0.2ml

Anti-MTF-1/FITC 熒光素標(biāo)記金屬反應(yīng)轉(zhuǎn)錄因子-1抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-CTSC/PALS/DPP-I/FITC 熒光素標(biāo)記組織蛋白酶C抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-Phospho-Stathmin (Ser16) /FITC 熒光素標(biāo)記磷酸化原癌基因蛋白18抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh CC85C 卷曲螺旋域蛋白質(zhì)85C抗體 規(guī)格 0.2ml

GADD153(Growth arrest and DNA damage-inducible 153) 生長抑制DNA損傷基因153抗原 0.5mg

ErbB 4 英文名稱： HER4抗體 0.1ml

Rhesus antibody Rh SLC39A6 SLC39A6抗體 規(guī)格 0.1ml

Anti-Phospho-Stathmin (Ser16) /FITC 熒光素標(biāo)記磷酸化原癌基因蛋白18抗體IgGMulti-class antibodies規(guī)格： 0.2ml

E1/UBAE(Human E1/ubiquitin-activating enzyme) ELISA Kit 人泛素激活酶Multi-class antibodies規(guī)格： 48T

Anti-NR2D/NMDAR2D 谷氨酸受體2D抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh IGF2BP1/IMP1 胰島素樣生長因子ⅡmRNA結(jié)合蛋白1抗體 規(guī)格 0.2ml

Alpha-Fodrin IgG/IgA(Mouse anti-alpha-Fodrin IgG/IgA)ELISA Kit 小鼠抗α-胞襯蛋白抗體IgG/IgA 96T

Phospho-Paxillin(Tyr31) 英文名稱： 磷酸化樁蛋白Paxillin抗體 0.1ml

CCDC152 英文名稱： 卷曲螺旋結(jié)構(gòu)域蛋白152抗體 0.1ml

Anti-NR2D/NMDAR2D 谷氨酸受體2D抗體Multi-class antibodies規(guī)格： 0.1ml

CL-0259BC-020(人癌細(xì)胞)5×106cells/瓶×2

FAM171B Others Human 人 FAM171B / KIAA1946 人細(xì)胞裂解液 (陽性對(duì)照)

人顱骨造骨細(xì)胞cDNAHCO cDNA

豬腎細(xì)胞;PK(15) 細(xì)胞，F(xiàn)O細(xì)胞 G422細(xì)胞，KM小鼠腦神經(jīng)膠質(zhì)母細(xì)胞瘤瘤株

表達(dá)SV40T和EBNA1的人胚腎細(xì)胞;293ET

HA Others H5N1 甲型 H5N1 (A/Egypt/2321-NAMRU3/2007) 血凝素 (Hemagglutinin / HA) 人細(xì)胞裂解液 (陽性對(duì)照)

CL-0257BC-009(人癌細(xì)胞)5×106cells/瓶×2

RP2 Others Human 人 XRP2 / RP2 桿狀病毒-昆蟲細(xì)胞裂解液 (陽性對(duì)照)

人成纖維細(xì)胞cDNAHPrF cDNA

C6細(xì)胞，腦細(xì)胞 人肺巨細(xì)胞癌細(xì)胞,HLAmP細(xì)胞 肺大動(dòng)脈平滑肌細(xì)胞Many types of cells包裝：5 × 105次方(1ml)

犬腎細(xì)胞;MDCK(NBL-2)

EM1 Others Human 人 EM1 人細(xì)胞裂解液 (陽性對(duì)照)

抑制基因抗體（野生型P53）說明書 NA Others H1N1 甲型 H1N1 (A/California/04/2009) 神經(jīng)氨酸酶 (Neuraminidase / NA) (N295S mutation) 人細(xì)胞裂解液 (陽性對(duì)照)

CL-0218SPC-A-1(人細(xì)胞)5×106cells/瓶×2

人真皮成纖維細(xì)胞-cDNAHDF-a cDNA

豬腎傳代細(xì)胞;IBRS-2 細(xì)胞，MG-63細(xì)胞 LLT細(xì)胞，小鼠Lewis瘤株

人晶體上皮細(xì)胞永生系;SRA01/04(HLE)

HA Others H10N3 甲型 H10N3 (A/duck/Hong Kong/786/1979) 血凝素HA1 (Hemagglutinin) 人細(xì)胞裂解液 (陽性對(duì)照)

技術(shù)外包服務(wù):

★抑制基因抗體（野生型P53）說明書 分子生物學(xué)：質(zhì)粒抽提、PCR、Q-PCR、RT-PCR、分子生物學(xué)：基因合成、引物合成、基因測(cè)序、載體構(gòu)建等

★蛋白工程：原核、哺乳動(dòng)物蛋白表達(dá)系統(tǒng)等

★病毒包裝：腺病毒、慢病毒等

★抗體工程：磁珠分選、病理染色、WB、ELISA、IP、IF、IHC、FACS、Confocal等等

★細(xì)胞工程：細(xì)胞表型分析(凋亡、增殖、周期、遷移、侵襲、修復(fù)、克隆形成)、細(xì)胞培養(yǎng)、細(xì)胞膜制備、穩(wěn)定細(xì)胞株構(gòu)建、細(xì)胞RNAi技術(shù)等等。